Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06881992 | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | PHASE3 | RECRUITING | 16 | — | — | Apr 16, 2025 | Sep 1, 2027 | May 18, 2026 | 13 | United States, France +3 |
| Arm | Type | Description |
|---|---|---|
| Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors) | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Ersodetug | DRUG | Ersodetug (9 mg/kg) + SOC |
Inclusion Criteria: * The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist * Male or female participants of ≥18 years of age who provide written informed consent. * Clinical diagnosis of neuroendocrine tumor (NET)...